ESPR

Esperion TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$3.55

+13.1% vs current

Most likely

Base case

60%

Probability

Target price

$3.18

+1.3% vs current

B-

Bear case

20%

Probability

Target price

$2.25

-28.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-14

AI commentary

Current sentiment is primarily event-driven. Recent trusted-news coverage in the packet focused on the ARCHIMED-backed take-private transaction, and the May 13, 2026 anchor price of $3.12 versus $3.16 cash consideration suggests the market is pricing a high likelihood of closing but assigning limited value to the CVR. Coverage is thin and no confirmed post-deal analyst revision set was checked, so this remains a cautious monitoring memo rather than a fresh bullish thesis.

RankAlpha Sentiment Codex - 2026-05-14

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventNear-term ex-U.S. label expansion milestonesMedium impact

Esperion disclosed in the Q1 2026 10-Q that NEXLETOL approval in Canada was received in Q4 2025, NEXLIZET approval in Canada was expected in the first half of 2026, and partner-led filings in Israel and Australia were tracking to 2026 decisions. These are incremental rather than thesis-changing, but they can support the partnership and royalty narrative if delivered on time [#10-Q-2026-05-08].

2026-09-30eventPending take-private closing in Q3 2026High impact

Esperion entered a merger agreement on May 1, 2026 under which holders would receive $3.16 per share in cash plus one CVR per share, with contingent payments up to $100 million in aggregate, and the company said the merger is expected to close in the third quarter of 2026 [#8-K-2026-05-01].

2026-12-31catalystCorstasis and Enbumyst integrationHigh impact

The Q1 2026 10-Q says Esperion completed the Corstasis merger on April 2, 2026 for $75 million upfront, with additional milestone and royalty-linked obligations, adding Enbumyst as a commercial cardiovascular asset. Early commercial execution will determine whether the acquired asset meaningfully broadens revenue beyond the core lipid franchise [#10-Q-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-14 • Updated nightlySource: Internal modelMethodology